Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼® ȯÀÚ¿¡¼ ¹ß»ýÇÑ ¸¸¼º °áÀý¼º Åëdz Ä¡·á 1¿¹
Febuxostat for the Treatment of Chronic Tophaceous Gout in a Patient on Continuous Ambulatory Peritoneal Dialysis
´ëÇѳ»°úÇÐȸÁö 2015³â 89±Ç 2È£ p.229 ~ p.232
À±Á¤Èñ(Yun Jeong-Hee) - ±è¿ø¹¬±â³ä ºÀ»ýº´¿ø ³»°ú
±èÈñ¿¬(Kim Hee-Yeoun) - ±è¿ø¹¬±â³ä ºÀ»ýº´¿ø ³»°ú
±èµ¿ÇÑ(Kim Dong-Han) - ±è¿ø¹¬±â³ä ºÀ»ýº´¿ø ³»°ú
¿ÀÁؼ®(Oh Joon-Seok) - ±è¿ø¹¬±â³ä ºÀ»ýº´¿ø ³»°ú
±è¼º¹Î(Kim Sung-Min) - ±è¿ø¹¬±â³ä ºÀ»ýº´¿ø ³»°ú
½Å¿ëÈÆ(Shin Yong-Hun) - ±è¿ø¹¬±â³ä ºÀ»ýº´¿ø ³»°ú
±èÁß°æ(Kim Joong-Kyung) - ±è¿ø¹¬±â³ä ºÀ»ýº´¿ø ³»°ú
Abstract
FebuxostatÀº ºñÇ»¸°°è ¼±ÅÃÀû XO ¾ïÁ¦Á¦·Î ½Å±â´É ÀúÇÏ È¯ÀÚ¿¡¼µµ ¿ë·®À» Á¶ÀýÇÒ ÇÊ¿ä°¡ ¾ø°í Ưº°ÇÑ ºÎÀÛ¿ëÀÌ ¾øÀÌ ¿ä»ê°ÇÏ È¿°ú°¡ ÁÁ´Ù. ÀúÀÚµéÀº º¹¸·Åõ¼® ȯÀÚ¿¡¼ »ý±ä ¸¸¼º °áÀý¼º Åëdz Ä¡·á¿¡ febuxostatÀ» Åõ¿©ÇÏ¿© tophi Àç¹ß ¾øÀÌ Ç÷û¿ä»ê³óµµ¸¦ ¸ñǥġ·Î ³·°Ô À¯ÁöÇÒ ¼ö ÀÖ¾ú´ø Áõ·Ê¸¦ °æÇèÇÏ¿´±â¿¡ ¹®Çå°íÂû°ú ÇÔ²² º¸°íÇÏ´Â ¹ÙÀÌ´Ù.
Hyperuricemic patients with gouty arthritis or tophi, a serum uric acid concentration of 8.0 mg/dL or higher, and complications should be treated with urate-lowering drugs. Conventionally, allopurinol is used to treat hyperuricemia and gout, but it is necessary to adjust the dosage according to the degree of renal impairment. Uncommonly, allopurinol may have severe or fatal side effects. The non-purine xanthine oxidase inhibitor febuxostat undergoes hepatic metabolism and may require less dose adjustment in association with renal function. It is considered to be an alternative treatment for hyperuricemic patients with chronic kidney disease. Our experience suggests that low-dose febuxostat is a promising alternative to allopurinol for the treatment of gouty arthritis or tophi in peritoneal dialysis patients.
Å°¿öµå
¸»±â½ÅºÎÀü, Åëdz °áÀý, ÆäºÏ¼Ò½ºÅÈ
Chronic kidney failure, Tophi, Febuxostat
KMID :
0882420150890020229
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
low-dose febuxostat is a promising alternative to allopurinol for the treatment of gouty arthritis or tophi in peritoneal dialysis patients.